Please select the option that best describes you:
In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy?
Do you stop therapy at 2 years or continue until progression of disease?
Answer from: at Academic Institution
If they have no evidence of disease on their scan, I stop at 2 years.
Sign in or Register to read more